monoclonal antibodies

Sharon Kantanie, center, participated in the study of a drug that reduced soft-tissue flare-ups and the prevented new areas of abnormal bone formation. With her are, from left, Emily Shardelow, clinical/translational research coordinator; Sharon’s parents, Mary and Stan Kantanie; Margo Black, MSN, manager of research projects for Metabolic Bone Disorders; and Kathryn Dahir, MD, professor of Endocrinology and Diabetes. (photo by Erin O. Smith)
September 28, 2023

Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva

A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.

By Jill Clendening
September 13, 2023

James Crowe’s antibody research lands American Society for Microbiology Award

Vanderbilt University Medical Center’s James Crowe Jr., MD, has been named to receive the 2024 American Society for Microbiology Award for Applied and Biotechnological Research.

By Bill Snyder
October 6, 2022

Vanderbilt’s Crowe receives the Building the Foundation Award from Research!America

Vanderbilt’s James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization.

By Bill Snyder
Shown here is the research team that discovered monoclonal antibodies that protect against COVID-19 in high-risk individuals.
August 24, 2022

COVID antibody research conducted at VUMC lands national award

A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.

By Bill Snyder
March 10, 2022

Technique hastens COVID-19 antibody discovery

Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.

By Bill Snyder
Crystal Wix, RN, foreground, and care partner Carolyn Forgac work with a patient in the COVID intensive care unit in September 2021.
March 3, 2022

COVID-19: two years of challenges, lessons, victories

Two years ago this week, the cataclysmic coronavirus known as SARS-CoV-2 arrived in Middle Tennessee.

By Bill Snyder
February 17, 2022

Pandemic leads to broader use of monoclonal antibodies

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.
By Bill Snyder
January 20, 2022

Omicron evades some but not all monoclonal antibodies: study

A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.
By Bill Snyder
December 9, 2021

Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization

The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which  protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
By Bill Snyder
December 2, 2021

Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms

By Bill Snyder
October 28, 2021

Zost honored for research on COVID-19, other life-threatening viral diseases

Vanderbilt's Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases. 
By Bill Snyder
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
By Bill Snyder
September 8, 2021

VUMC antibodies help neutralize two deadly viruses: study

Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.
By Bill Snyder
1 2 3 4